| A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ... Clinical Cancer Research 24 (18), 4482-4493, 2018 | 104 | 2018 |
| Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance EA Pietilä, J Gonzalez-Molina, L Moyano-Galceran, S Jamalzadeh, ... Nature communications 12 (1), 3904, 2021 | 100 | 2021 |
| Adaptive RSK‐EphA2‐GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer L Moyano‐Galceran, EA Pietilä, SP Turunen, S Corvigno, E Hjerpe, ... EMBO molecular medicine 12 (4), e11177, 2020 | 49 | 2020 |
| Culture and drug profiling of patient derived malignant pleural effusions for personalized cancer medicine C Ruiz, S Kustermann, E Pietilae, T Vlajnic, B Baschiera, L Arabi, T Lorber, ... PLoS One 11 (8), e0160807, 2016 | 17 | 2016 |
| Multi‐modal meta‐analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor A Jaiswal, P Gautam, EA Pietilä, S Timonen, N Nordström, Y Akimov, ... Molecular systems biology 17 (3), e9526, 2021 | 10 | 2021 |
| PTPRA phosphatase regulates GDNF-dependent ret signaling and inhibits the RET mutant MEN2A oncogenic potential L Yadav, E Pietilä, T Öhman, X Liu, AK Mahato, Y Sidorova, K Lehti, ... IScience 23 (2), 2020 | 10 | 2020 |
| Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality J Jukonen, L Moyano-Galceran, K Höpfner, EA Pietilä, L Lehtinen, ... Scientific reports 11 (1), 8856, 2021 | 9 | 2021 |
| Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis S Benay, C Meille, S Kustermann, I Walter, A Walz, PA Gonsard, ... Journal of Pharmacokinetics and Pharmacodynamics 42, 275-285, 2015 | 3 | 2015 |
| Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancer AS Nagaraj, M Salko, A Sirsikar, EP Erkan, EA Pietilä, I Niemiec, J Bao, ... bioRxiv, 2024.02. 15.579904, 2024 | 1 | 2024 |
| Abstract PR-007: Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous … A Färkkilä, AS Nagaraj, EA Pietilä, M Salko, EP Erkan, I Niemiec, ... Cancer Research 84 (5_Supplement_2), PR-007-PR-007, 2024 | | 2024 |
| 2022-RA-961-ESGO Real-world prospective characterization of homologous recombination deficiency in advanced ovarian cancer M Salko, F Perez-Villatoro, J Aldahdooh, A Chernenko, E Pietilä, ... International Journal of Gynecologic Cancer 32 (Suppl 2), 2022 | | 2022 |
| Cancer cell-microenvironment communication in tumor progression and therapy resistance E Pietilä Helsingin yliopisto, 2022 | | 2022 |
| Abstract A64: Extracellular matrix proteins increase invasive growth and chemotherapy resistance of ovarian cancer cells EA Pietilä, J Gonzales-Molina, L Moyano-Galceran, L Lehtinen, ... Clinical Cancer Research 26 (13_Supplement), A64-A64, 2020 | | 2020 |
| Abstract GMM-041: OVARIAN CANCER CELLS INDUCE A FEEDBACK RESPONSE TO PLATINUM-BASED CHEMOTHERAPY BY ACTIVATING AN ONCOGENIC RSK-EPHA2-GPRC5A SIGNALING SWITCH L Moyano-Galceran, SP Turunen, E Pietilä, T Alkasalias, S Corvigno, ... Clinical Cancer Research 25 (22_Supplement), GMM-041-GMM-041, 2019 | | 2019 |
| Abstract GMM-057: A FUNCTIONAL HOMOLOGOUS RECOMBINATION ASSAY PREDICTS PRIMARY CHEMOTHERAPY RESPONSE AND LONG-TERM SURVIVAL IN OVARIAN CANCER PATIENTS M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, A Alkodsi, Y Li, ... Clinical Cancer Research 25 (22_Supplement), GMM-057-GMM-057, 2019 | | 2019 |
| Novel Tumor Suppressor PTPRA Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential L Yadav, E Pietilä, T Öhman, X Liu, AK Mahato, K Lehti, M Saarma, ... Available at SSRN 3439661, 2019 | | 2019 |
| Population Approach Group Europe Population Approach Group Europe R Keizer | | |
